ÈËÆÞÖгöÊÓƵ

Jonathan D. Tward
( out of 168 reviews )

Jonathan D. Tward, MD, PhD, FASTRO

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital South

Radiation Oncology
Salt Lake City
801-581-2396

  • Jonathan Tward, MD, Ph.D., is a tenured Professor in the Department of Radiation Oncology. He is recognized as a major authority and key-opinion leader in treating prostate, bladder, and penile cancers. He holds the The Vincent P. and Janet Mancini Presidential Endowed Chair at Huntsman Cancer Institute in Genitourinary Malignancies. Tward is the leader of the Huntsman Cancer Institute's (HCI) Genitourinary Cancers Center (GUCC), coordinating the activities of its approximately 100 members who represent 45 of the ÈËÆÞÖгöÊÓƵ of Utah or HCI Departments or Colleges, and 21 Interdisciplinary Programs. As the leader, Tward is responsible for the strategic vision of the GUCC, and its operations, by directing multidisciplinary collaboration of patient care, community engagement, research, and donor relations. Tward also serves as the physician lead on several operational committees and working groups within the Department of Radiation Oncology.

    Dr. Tward is an expert at delivering highly precise and targeted radiation therapy to people afflicted with cancers of the prostate, bladder, kidney, testis, and penis. He uses the vast array of technologies available at the HCI to deliver intensity-modulated radiotherapy (IMRT), image-guided radiotherapy (IGRT), stereotactic body radiotherapy (SBRT), as well as low-dose-rate (LDR) and high-dose-rate (HDR) brachytherapy.

    As a practicing physician and scientist, mentor, and educator, Tward has contributed to over 100 published-peer reviewed journal articles. He is the Principal Investigator (PI) on several ongoing investigator-initiated clinical trials and is the site PI on numerous cooperative group or industry-sponsored clinical trials. Tward has received grant funding for his research interests which include "Big Data" analytics, diagnostic biomarker development, comparative effectiveness outcomes studies, and clinical trials. Tward serves as the Utah State Captain for the American Society of Radiation Oncology (ASTRO) and is a strong advocate for cancer patients through federal and state advocacy efforts with Utah's elected federal representatives. He serves on the National Comprehensive Cancer Networks (NCCN) clinical practice guidelines committees for prostate, bladder, and penile cancers. These clinical practice guidelines are internationally recognized standards for clinical direction and policy in cancer care. As a member of the NCCN Framework for Resource Stratification subcommittees, Tward helps define appropriate cancer treatment pathways of low- and middle-resource countries where specific diagnostic tests or treatment approaches may be unavailable.

    Tward earned a bachelor's degree in biology at the ÈËÆÞÖгöÊÓƵ of California, Los Angeles, a Ph.D. in biochemistry, and an MD at Tufts ÈËÆÞÖгöÊÓƵ in Boston, Massachusetts. He completed a residency in radiation oncology at the ÈËÆÞÖгöÊÓƵ of Utah. Before joining HCI, Tward founded and served as the CEO or on the Board of Directors for several pioneering e-commerce and health-related websites.

    Specialties

    Patient Rating

    5.0 /5
    ( out of 168 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    September 28, 2024
    HUNTSMAN CANCER CENTER

    DR. J0NATHAN D. TWARD, MD, DOES SUCH AN OUTSTANDING JOB OF PUTTING HIS PATIENTS AT EASE WHILE TAKING ALL THE TIME TO ANSWER ALL OF OUR QUESTIONS RELATIVE TO THE TREATMENT OPTIONS FOR MY PRESENT PROSTRATE CANCER ISSUES AT THIS TIME. DR. TWARD IS A DEFINITE CREDIT TO HIMSELF AND THE UNIVERSITY OF UTAH'S HUNTSMAN RADIOLOGY ONCOLGY DEPARTMENT. THE UNIVERSITY OF UTAH AND THE HUNTSMAN CANCER HOSPITAL RADIOLOGY AND ONCOLOGY DEPARTMENT ARE VERY LUCKY TO HAVE MEDICAL RADIOLOGY AND ONCOLOGY DOCTORS IN THEIR EMPLOY.. DR. TWARD IS DEFINITELY AN OUTSTANDING CREDIT TO HIMSELF AND TO THE HUNTSMAN CANCER HOSPITAL TO WHICH HE IS EMPLOYED.

    September 01, 2024
    HUNTSMAN CANCER CENTER

    I have a great degree of confidence in Dr. Tward. I have been his patient for over a decade; his expertise, advice, friendly manner and sincere concern for me, have been a an important support for me. It is greatly appreciated.

    July 19, 2024
    HUNTSMAN CANCER CENTER

    Dr. Tward is a kind and caring human beings filled with compassion for those under his care. His gentle manner is calming and healing. Dr. Tward tased the time in his busy schedule to engage you in your journey of healin. My encounter with cancer has been made easy with his, knowledge, wisdom and care. I am grateful to be his patience.

    July 09, 2024
    HUNTSMAN CANCER CENTER

    He is friendly, spent over an hour to answer questions, and explain therapy. His approach gave me confidence.

    June 13, 2024
    HUNTSMAN CANCER CENTER

    Awesome and truthful doctor. I'd trust him with my life! Wait a minute... I just did!

    June 02, 2024
    HUNTSMAN CANCER CENTER

    Outstanding in knowledge and caring.

    May 31, 2024
    HUNTSMAN CANCER CENTER

    Outstanding, was impressed 5 years ago when he took my case and still am!

    May 30, 2024
    HUNTSMAN CANCER CENTER

    Dr. Tward was outstanding. He answered all my questions clearly and straightforward. Talked in lay terms rather than medical jargon. Great bedside manner.

    May 24, 2024
    HUNTSMAN CANCER CENTER

    A wonderful man / doctor.

    See More Patient Comments

  • Jonathan Tward, MD, Ph.D., is a tenured Professor in the Department of Radiation Oncology. He is recognized as a major authority and key-opinion leader in treating prostate, bladder, and penile cancers. He holds the The Vincent P. and Janet Mancini Presidential Endowed Chair at Huntsman Cancer Institute in Genitourinary Malignancies. Tward is the leader of the Huntsman Cancer Institute's (HCI) Genitourinary Cancers Center (GUCC), coordinating the activities of its approximately 100 members who represent 45 of the ÈËÆÞÖгöÊÓƵ of Utah or HCI Departments or Colleges, and 21 Interdisciplinary Programs. As the leader, Tward is responsible for the strategic vision of the GUCC, and its operations, by directing multidisciplinary collaboration of patient care, community engagement, research, and donor relations. Tward also serves as the physician lead on several operational committees and working groups within the Department of Radiation Oncology.

    Dr. Tward is an expert at delivering highly precise and targeted radiation therapy to people afflicted with cancers of the prostate, bladder, kidney, testis, and penis. He uses the vast array of technologies available at the HCI to deliver intensity-modulated radiotherapy (IMRT), image-guided radiotherapy (IGRT), stereotactic body radiotherapy (SBRT), as well as low-dose-rate (LDR) and high-dose-rate (HDR) brachytherapy.

    As a practicing physician and scientist, mentor, and educator, Tward has contributed to over 100 published-peer reviewed journal articles. He is the Principal Investigator (PI) on several ongoing investigator-initiated clinical trials and is the site PI on numerous cooperative group or industry-sponsored clinical trials. Tward has received grant funding for his research interests which include "Big Data" analytics, diagnostic biomarker development, comparative effectiveness outcomes studies, and clinical trials. Tward serves as the Utah State Captain for the American Society of Radiation Oncology (ASTRO) and is a strong advocate for cancer patients through federal and state advocacy efforts with Utah's elected federal representatives. He serves on the National Comprehensive Cancer Networks (NCCN) clinical practice guidelines committees for prostate, bladder, and penile cancers. These clinical practice guidelines are internationally recognized standards for clinical direction and policy in cancer care. As a member of the NCCN Framework for Resource Stratification subcommittees, Tward helps define appropriate cancer treatment pathways of low- and middle-resource countries where specific diagnostic tests or treatment approaches may be unavailable.

    Tward earned a bachelor's degree in biology at the ÈËÆÞÖгöÊÓƵ of California, Los Angeles, a Ph.D. in biochemistry, and an MD at Tufts ÈËÆÞÖгöÊÓƵ in Boston, Massachusetts. He completed a residency in radiation oncology at the ÈËÆÞÖгöÊÓƵ of Utah. Before joining HCI, Tward founded and served as the CEO or on the Board of Directors for several pioneering e-commerce and health-related websites.

    Board Certification and Academic Information

    Academic Departments Radiation Oncology -Primary

    Education history

    Chief Resident Radiation Oncology - ÈËÆÞÖгöÊÓƵ of Utah School of Medicine Chief Resident
    Radiation Oncology - ÈËÆÞÖгöÊÓƵ of Utah School of Medicine Resident
    Internship Internal Medicine - ÈËÆÞÖгöÊÓƵ of Utah School of Medicine Intern
    Biochemistry - Tufts ÈËÆÞÖгöÊÓƵ Ph.D.
    Professional Medical Medicine - Tufts ÈËÆÞÖгöÊÓƵ School of Medicine M.D.
    Biology - UCLA B.S.

    Selected Publications

    Journal Article

    1. Tward JD, Huang HC, Esteva A, Mohamad O, van der Wal D, Simko JP, DeVries S, Zhang J, Joun S, Showalter TN, Schaeffer EM, Morgan TM, Monson JM, Wallace JA, Bahary JP, Sandler HM, Spratt DE, Rodgers JP, Feng FY, Tran PT (2024). Prostate Cancer Risk Stratification in NRG Oncology Phase III Randomized Trials Using Multimodal Deep Learning With Digital Histopathology. JCO Precis Oncol, 8, e2400145. ()
    2. Amann ES, Ose J, Hathaway CA, Oswald LB, Hardikar S, Himbert C, Chellam V, Lin T, Daniels B, Kirchhoff AC, Gigic B, Grossman D, Tward J, Varghese TK Jr, Shibata D, Figueiredo JC, Toriola AT, Beck A, Scaife C, Barnes CA, Matsen C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Grady WM, Schneider M, Dinkel A, Islam JY, Gonzalez BD, Otto AK, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples AR (2024). Risk factors and health behaviors associated with loneliness among cancer survivors during the COVID-19 pandemic. J Behav Med, 47(3), 405-421. ()
    3. Roach E, Hutten R, Johnson S, Suneja G, Tward J, Petereit D, Gaffney D (2024). The impact of a positive COVID-19 test on timeliness of radiation in patients receiving brachytherapy. Brachytherapy, 23(3), 360-367. ()
    4. Tward JD, Lenz L, Gutin A, Clegg W, Kasten CR, Finch R, Cohen T, Michalski J, Kishan AU (2024). Using the Cell-Cycle Risk Score to Predict the Benefit of Androgen-Deprivation Therapy Added to Radiation Therapy in Patients With Newly Diagnosed Prostate Cancer. JCO Precis Oncol, 8, e2300722. ()
    5. Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Buyyounouski MK, Chan K, Chang SS, Chang P, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kaimakliotis H, Kishan AU, Kundu S, Lele SM, Mamtani R, Mian OY, Michalski J, Montgomery JS, Parikh M, Patterson A, Peyton C, Plimack ER, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Stewart T, Sundi D, Tollefson M, Tward J, Wright JL, Cassara CJ, Gurski LA (2024). NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024. J Natl Compr Canc Netw, 22(4), 216-225. ()
    6. Schaeffer EM, Srinivas S, Adra N, An Y, Bitting R, Chapin B, Cheng HH, DAmico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Karnes RJ, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Szmulewitz R, Teply BA, Tward J, Valicenti R, Wong JK, Snedeker J, Freedman-Cass DA (2024). NCCN Guidelines® Insights: Prostate Cancer, Version 3.2024. J Natl Compr Canc Netw, 22(3), 140-150. ()
    7. Hutten RJ, Odei B, Johnson SB, Tward JD (2024). Validation of the Combined Clinical Cell-Cycle Risk Score to Prognosticate Early Prostate Cancer Metastasis From Biopsy Specimens and Comparison With Other Routinely Used Risk Classifiers. JCO Precis Oncol, 8, e2300364. ()
    8. Sung D, Schmidt B, Tward JD (2024). The Ability of the STAR-CAP Staging System to Prognosticate the Risk of Subsequent Therapies and Metastases After Initial Treatment of M0 Prostate Cancer. Clin Genitourin Cancer. ()
    9. Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, DAmico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Netto G, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Teply BA, Tward J, Valicenti R, Wong JK, Shead DA, Snedeker J, Freedman-Cass DA (2023). Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 21(10), 1067-1096. ()
    10. Hutten RJ, Weil CR, King AJ, Barney B, Bylund CL, Fagerlin A, Gaffney DK, Gill D, Scherer L, Suneja G, Tward JD, Warner EL, Werner TL, Whipple G, Evans J, Johnson SB (2023). Multi-Institutional Analysis of Cancer Patient Exposure, Perceptions, and Trust in Information Sources Regarding Complementary and Alternative Medicine. JCO Oncol Pract, 19(11), OP2300179. ()
    11. Fenlon JB, Nelson G, Teague KM, Coleman S, Shrieve D, Tward J (2023). A Dosimetric Correlation Between Radiation Dose to Bone and Reduction of Hemoglobin Levels After Radiotherapy for Prostate Cancer. Int J Radiat Oncol Biol Phys, 118(1), 85-93. ()
    12. Spratt DE, Tang S, Sun Y, Huang HC, Chen E, Mohamad O, Armstrong AJ, Tward JD, Nguyen PL, Lang JM, Zhang J, Mitani A, Simko JP, DeVries S, van der Wal D, Pinckaers H, Monson JM, Campbell HA, Wallace J, Ferguson MJ, Bahary JP, Schaeffer EM, Sandler HM, Tran PT, Rodgers JP, Esteva A, Yamashita R, Feng FY (2023). Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer. NEJM Evid, 2(8), EVIDoa2300023. ()
    13. Spratt DE, Tang S, Sun Y, Huang HC, Chen E, Mohamad O, Armstrong AJ, Tward JD, Nguyen PL, Lang JM, Zhang J, Mitani A, Simko JP, DeVries S, van der Wal D, Pinckaers H, Monson JM, Campbell HA, Wallace J, Ferguson MJ, Bahary JP, Schaeffer EM, Consortium NPCA, Sandler HM, Tran PT, Rodgers JP, Esteva A, Yamashita R, Feng FY (2023). Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer. ()
    14. Patel SA, Ma TM, Wong JK, Stish BJ, Dess RT, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Tran PT, Krauss DJ, Abu-Isa EI, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, DeWeese TL, Tilki D, Ciezki JP, Karnes RJ, Nickols NG, Rettig MB, Feng FY, Berlin A, Tward JD, Davis BJ, Reiter RE, Boutros PC, Romero T, Horwitz EM, Tendulkar RD, Steinberg ML, Spratt DE, Xiang M, Kishan AU (2022). External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis. Int J Radiat Oncol Biol Phys, 115(3), 645-653. ()
    15. Parsons MW, Rock C, Chipman JJ, Shah HR, Hu B, Stephens DM, Tao R, Tward JD, Gaffney DK (2022). Secondary malignancies in non-Hodgkin lymphoma survivors: 40 years of follow-up assessed by treatment modality. Cancer Med, 12(3), 2624-2636. ()
    16. Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, Bryce A, Chapin B, Cheng HH, DAmico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Netto G, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Teply BA, Tward J, Valicenti R, Wong JK, Berardi RA, Shead DA, Freedman-Cass DA (2022). NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023. J Natl Compr Canc Netw, 20(12), 1288-1298. ()
    17. Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kishan A, Kundu S, Lele SM, Mamtani R, Margulis V, Mian OY, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Parikh M, Patterson A, Plimack ER, Pohar KS, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Tollefson M, Tward J, Wright JL, Dwyer MA, Cassara CJ, Gurski LA (2022). NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw, 20(8), 866-878. ()
    18. Rock CB, Chipman JJ, Parsons MW, Weil CR, Hutten RJ, Tao R, Tward JD, Shah HR, Hu B, Stephens DM, Gaffney DK (2022). Second Primary Malignancies in Diffuse Large B-cell Lymphoma Survivors with 40 Years of Follow Up: Influence of Chemotherapy and Radiation Therapy. Adv Radiat Oncol, 7(6), 101035. ()
    19. Himbert C, Hathaway CA, Daniels B, Salas K, Ashworth A, Gigic B, Lin T, Viskochil R, Kirchhoff AC, Grossman D, Ose J, Tward J, Scaife C, Figueiredo JC, Toriola AT, Beck A, Shibata D, Gonzalez BD, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples AR (2022). Factors associated with changes in exercise behaviors during the COVID-19 pandemic. Cancer Causes Control, 33(7), 939-950. ()
    20. Hutten R, Khouri A, Parsons M, Tward A, Wilson T, Peterson J, Morrell G, Dechet C, ONeil B, Schmidt B, Kokeny K, Lloyd S, Cannon D, Tward J, Sanchez A, Johnson S (2022). The Clinical Significance of Maximum Tumor Diameter on MRI in Men Undergoing Radical Prostatectomy or Definitive Radiotherapy for Locoregional Prostate Cancer. Clin Genitourin Cancer, 20(6), e453-e459. ()
    21. Peoples AR, Oswald LB, Ose J, Daniels B, Himbert C, Hathaway CA, Gigic B, Kirchhoff AC, Lin T, Grossman D, Tward J, Varghese TK Jr, Figueiredo JC, Toriola AT, Beck A, Scaife C, Shibata D, LaStayo P, Gonzalez B, Salas K, Ashworth A, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM (2022). Impact of the COVID-19 pandemic on rural and urban cancer patients' experiences, health behaviors, and perceptions. J Rural ÈËÆÞÖгöÊÓƵ, 38(4), 886-899. ()
    22. Hutten R, Tward JD (2022). Nomograms for Metastasis-Free and Overall Survival for Pathologically Node Positive Prostate Cancer Patients Treated With or Without Radiation Therapy Plus Short-Term ADT. Clin Genitourin Cancer, 20, e263-e269. ()
    23. Wang KM, Rickards AJ, Bingham T, Tward JD, Price RG (2022). Technical note: Evaluation of a silicone-based custom bolus for radiation therapy of a superficial pelvic tumor. J Appl Clin Med Phys, 23(4), e13538. ()
    24. Kishan AU, Steigler A, Denham JW, Zapatero A, Guerrero A, Joseph D, Maldonado X, Wong JK, Stish BJ, Dess RT, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Tilki D, Karnes RJ, Tosoian JJ, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Jiang T, Ma TM, Xiang M, Philipson R, Chang A, Kupelian PA, Rettig MB, Feng FY, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Boutros PC, Horwitz EM, Tendulkar RD, Spratt DE, Romero T (2022). Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts. JAMA Oncol, 8, e216871. ()
    25. Ravi P, Pond GR, Diamantopoulos LN, Su C, Alva A, Jain RK, Skelton WP 4th, Gupta S, Tward JD, Olson KM, Singh P, Grunewald CM, Niegisch G, Lee JL, Gallina A, Bandini M, Necchi A, Mossanen M, McGregor BA, Curran C, Grivas P, Sonpavde GP (2021). Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration. BJU Int, 128(5), 607-614. ()
    26. Tward J, Lenz L, Flake DD II, Rajamani S, Olsson C, Kapoor DA, Mantz C, Liauw SL, Antic T, Shore N, Albertson D, Henderson J, Lee SP, Gay HA, Michalski J, Hung A, Raben D, Garraway I, Lewis MS, Nguyen PL, Marshall DT, Brawer MK, Stone S, Cohen T (2021). The Clinical Cell-Cycle Risk (CCR) score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation. Int J Radiat Oncol Biol Phys, 113(1), 66-76. ()
    27. Thomas JJ, Tward JD (2021). Stage Presentation, Care Patterns, Treatment Outcomes, and Impact of Radiotherapy on Overall Survival for Adrenocortical Carcinoma. Clin Genitourin Cancer, 19(5), 417-424. ()
    28. Kraus RD, Weil CR, Wells S, Tward JD, Groundland JS, Jones KB, Cannon DM (2021). Radiation Therapy in Conjunction With Surgical Stabilization of Impending or Pathologic Fractures Secondary to Metastasis: Is There a Difference Between Single and Multifraction Regimens? Adv Radiat Oncol, 7(2), 100795. ()
    29. Tward JD, Schlomm T, Bardot S, Canter DJ, Scroggins T, Freedland SJ, Lenz L, Flake DD 2nd, Cohen T, Brawer MK, Stone S, Bishoff J (2021). Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-cycle Risk (CCR) Score Threshold for Prognosticating Benefit From Multimodality Therapy. Clin Genitourin Cancer, 19(4), 296-304.e3. ()
    30. Tward AE, Tward JD (2021). The Stage at Presentation and Oncologic Outcomes for Agent Orange Exposed and Non-Exposed United States Veterans Diagnosed With Prostate Cancer. Clin Genitourin Cancer, 19(4), 369-369.e7. ()
    31. Philipson RG, Romero T, Wong JK, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Braccioforte M, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Valle L, Chong N, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Tilki D, Karnes RJ, Klein EA, Tosoian JJ, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Kupelian PA, Rettig MB, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Kishan AU (2021). Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. Eur Urol, 80(2), 142-146. ()
    32. Johnson SB, Parsons M, Dorff T, Moran MS, Ward JH, Cohen SA, Akerley W, Bauman J, Hubbard J, Spratt DE, Bylund CL, Swire-Thompson B, Onega T, Scherer LD, Tward J, Fagerlin A (2021). Cancer Misinformation and Harmful Information on Facebook and Other Social Media: A Brief Report. J Natl Cancer Inst, 114, 1036-1039. ()
    33. Kishan AU, Karnes RJ, Romero T, Wong JK, Motterle G, Tosoian JJ, Trock BJ, Klein EA, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Levin-Epstein R, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Braccioforte M, Huland H, Tran PT, Martin S, Martnez-Monge R, Krauss DJ, Abu-Isa EI, Alam R, Schwen Z, Chang AJ, Pisansky TM, Choo R, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Chong N, Kupelian PA, DAmico AV, Rettig MB, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Tilki D (2021). Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. JAMA Netw Open, 4(7), e2115312. ()
    34. Hutten RJ, Parsons MW, Weil CR, Tward JD, Lloyd S, Sanchez A, Lester-Coll N, Johnson SB (2021). Temporal Trends and Predictors in Diagnosing Pathologic Node-Positive Prostate Cancer in Clinically Node-Negative Patients. Clin Genitourin Cancer, 19(6), e360-e366. ()
    35. Greenberg SE, Hunt TC, Ambrose JP, Lowrance WT, Dechet CB, ONeil BB, Tward JD (2021). Clinical Germline Testing Results of Men With Prostate Cancer: Patient-Level Factors and Implications of NCCN Guideline Expansion. JCO Precis Oncol, 5. ()
    36. Jairath NK, Dal Pra A, Vince R Jr, Dess RT, Jackson WC, Tosoian JJ, McBride SM, Zhao SG, Berlin A, Mahal BA, Kishan AU, Den RB, Freedland SJ, Salami SS, Kaffenberger SD, Pollack A, Tran P, Mehra R, Morgan TM, Weiner AB, Mohamad O, Carroll PR, Cooperberg MR, Karnes RJ, Nguyen PL, Michalski JM, Tward JD, Feng FY, Schaeffer EM, Spratt DE (2020). A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. Eur Urol, 79(3), 374-383. ()
    37. Schaeffer E, Srinivas S, Antonarakis ES, Armstrong AJ, Bekelman JE, Cheng H, DAmico AV, Davis BJ, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Horwitz EM, Ippolito JE, Kuettel MR, Lang JM, McKay R, McKenney J, Netto G, Penson DF, Pow-Sang JM, Reiter R, Richey S, Roach Iii M, Rosenfeld S, Shabsigh A, Spratt DE, Teply BA, Tward J, Shead DA, Freedman-Cass DA (2021). NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. J Natl Compr Canc Netw, 19(2), 134-143. ()
    38. Hutten RJ, Weil CR, Tward JD, Lloyd S, Johnson SB (2021). Patterns of Care and Treatment Outcomes in Locoregional Squamous Cell Carcinoma of the Prostate. Eur Urol Open Sci, 23, 30-33. ()
    39. Szegedi M, Boehm C, Paxton A, Rassiah-Szegedi P, Sarkar V, Zhao H, Su F, Kokeny KE, Lloyd S, Tward J, Salter BJ (2020). Comparison of transperineal ultrasound image guidance technique to transabdominal technique for prostate radiation therapy. Med Phys, 47(12), 6113-6121. ()
    40. Tward JD, ONeil B, Boucher K, Kokeny K, Lowrance WT, Lloyd S, Cannon D, Stephenson RA, Agarwal N, Farr T, Petragallo R, Sherar NZ, Kunz I, Hofer A, Courdy S, Shrieve DC, Dechet C (2020). Metastasis, Mortality, and Quality of Life for Men With NCCN High and Very High Risk Localized Prostate Cancer After Surgical and/or Combined Modality Radiotherapy. Clin Genitourin Cancer, 18(4), 274-283.e5. ()
    41. McComas K, Agarwal N, Bowen G, Maughan BL, Tward JD (2020). Definitive Chemoradiotherapy for Locally Advanced, Lymph-node Positive, Nonmetastatic Penile Squamous Cell Carcinoma.  In Press.  Available online at  DOI:  https://doi.org/10.1016/j.clgc.2020.02.007. Clin Genitourin Cancer.
    42. Canter DJ, Freedland S, Rajamani S, Latsis M, Variano M, Halat S, Tward J, Cohen T, Stone S, Schlomm T, Bishoff J, Bardot S (2019). Analysis of the prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with definitive therapy. Prostate Cancer Prostatic Dis, 23(1), 102-107. ()
    43. Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chang S, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Guzzo T, Herr HW, Hoffman-Censits J, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wright JL, Gurski LA, Johnson-Chilla A (2020). Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 18(3), 329-354. ()
    44. Usera BM, Creveling P, Tward JD (2020). Impact and Outcomes of Pretreatment Total Serum Testosterone on Localized Prostate Cancer Patients. Prostate Cancer, 2020, 8357452. ()
    45. Solanki AA, Savir-Baruch B, Liauw SL, Michalski J, Tward JD, Vapiwala N, Teoh EJ, LOCATE study group (2020). 18F-Fluciclovine Positron Emission Tomography in Men With Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Planning to Undergo Salvage Radiation Therapy: Results from LOCATE. Pract Radiat Oncol, 10(5), 354-362. ()
    46. Greenberg S, Tward J, ONeil B (2019). Germline Variants in Highly Selected Patients With Prostate Cancer. JAMA Oncol, 5(9), 1368-1369. ()
    47. Zhao H, Sarkar V, Wang B, Rassiah-Szegedi P, Szegedi M, Jessica Huang Y, Huang L, Tward J, Salter B (2019). Calculation of delivered composite dose from Calypso tracking data for prostate cancer: And subsequent evaluation of reasonable treatment interruption tolerance limits. J Appl Clin Med Phys, 20(8), 105-113. ()
    48. Tward JD, Poppe MM, Hitchcock YJ, ONeil B, Albertson DJ, Shrieve DC (2018). Demographics, stage distribution, and relative roles of surgery and radiotherapy on survival of persons with primary prostate sarcomas. Cancer Med, 7(12), 6030-6039. ()
    49. Sarkar V, Lloyd S, Paxton A, Huang L, Su FC, Tao R, Tward J, Zhao H, Salter B (2018). Daily breathing inconsistency in pancreas SBRT: a 4DCT study. J Gastrointest Oncol, 9(6), 989-995. ()
    50. Tward J (2018). The case for nonsurgical therapy of nonmetastatic penile cancer. Nat Rev Urol, 15(9), 574-584. ()
    51. Lin DW, Crawford ED, Keane T, Evans B, Reid J, Rajamani S, Brown K, Gutin A, Tward J, Scardino P, Brawer M, Stone S, Cuzick J (2018). Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. Urol Oncol, 36(6), 310.e7-310.e13. ()
    52. Frandsen J, Orton A, Jensen R, Colman H, Cohen AL, Tward J, Shrieve DC, Suneja G (2018). Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database. J Neurosurg, 128(4), 1133-1138. ()
    53. Burt LM, Shrieve DC, Tward JD (2018). Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database. Adv Radiat Oncol, 3(2), 170-180. ()
    54. Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA (2017). Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 15(10), 1240-1267. ()
    55. Du K, Zhang C, Presson AP, Tward JD, Brant WO, Dechet CB (2017). Orgasmic Function after Radical Prostatectomy. J Urol, 198(2), 407-413. ()
    56. Frandsen J, Orton A, Shrieve D, Tward J (2017). Risk of Death from Prostate Cancer with and without Definitive Local Therapy when Gleason Pattern 5 is Present: A Surveillance, Epidemiology, and End Results Analysis. Cureus, 9(7), e1453. ()
    57. Mayer EN, Tward JD, Bassett M, Lenherr SM, Hotaling JM, Brant WO, Lowrance WT, Myers JB (2017). Management of Radiation Therapy Oncology Group grade 4 urinary adverse events after radiotherapy for prostate cancer. BJU Int, 119(5), 700-708. ()
    58. Lindsay M Burt, Matthew Poppe, Kristine E Kokeny, David K Gaffney, Dennis C Shrieve, Jonathan D Tward (3/1/2017). Comparison of Treatment Modalities for Breast Cancer Arising In Hodgkin’s Lymphoma Survivors. J Radiat Oncol, 6(1), 65-72.
    59. Bassett MR, Santiago-Lastra Y, Stoffel JT, Goldfarb R, Elliott SP, Pate SC, Broghammer JA, Gaither T, Breyer BN, Vanni AJ, Voelzke BB, Erickson BA, McClung CD, Presson AP, Tward JD, Myers JB, Neurogenic Bladder Research Group, Trauma and Urologic Reconstructive Network of Surgeons (2017). Urinary Diversion for Severe Urinary Adverse Events of Prostate Radiation: Results from a Multi-Institutional Study. J Urol, 197(3 Pt 1), 744-750. ()
    60. Salter BJ, Szegedi M, Boehm C, Sarkar V, Rassiah-Szegedi P, Wang B, Zhao H, Huang J, Huang L, Kokeny K, Tward JD (2017). Comparison of 2 transabdominal ultrasound image guidance techniques for prostate and prostatic fossa radiation therapy. Pract Radiat Oncol, 7(2), e99-e107. ()
    61. Gonzalez VJ, Hullett CR, Burt L, Rassiah-Szegedi P, Sarkar V, Tward JD, Hazard LJ, Huang YJ, Salter BJ, Gaffney DK (2017). Impact of prone versus supine positioning on small bowel dose with pelvic intensity modulated radiation therapy. Adv Radiat Oncol, 2(2), 235-243. ()
    62. Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C (2016). NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw, 14(10), 1213-1224. ()
    63. Tward JD, Jarosek S, Chu H, Thorpe C, Shrieve DC, Elliott S (2016). Time Course and Accumulated Risk of Severe Urinary Adverse Events After High- Versus Low-Dose-Rate Prostate Brachytherapy With or Without External Beam Radiation Therapy. Int J Radiat Oncol Biol Phys, 95(5), 1443-1453. ()
    64. Merriman J, Tward J, Albertson D, Dechet C, Agarwal N (2016). Durable Response to Treatment With Combination Radiotherapy and High-dose Interleukin-2 in Metastatic Chromophobe Variant Renal Cell Carcinoma. J Immunother, 39(2), 101-3. ()
    65. Mohler JL, Armstrong AJ, Bahnson RR, DAmico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Kane CJ, Kawachi MH, Kuettel M, Lee RJ, Meeks JJ, Penson DF, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M 3rd, Rosenfeld S, Schaeffer E, Skolarus TA, Small EJ, Sonpavde G, Srinivas S, Strope SA, Tward J, Shead DA, Freedman-Cass DA (2016). Prostate Cancer, Version 1.2016. J Natl Compr Canc Netw, 14(1), 19-30. ()
    66. Ly D, Bagshaw HP, Anker CJ, Tward JD, Grossmann KF, Jensen RL, Shrieve DC (2015). Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment. J Neurosurg, 123(2), 395-401. ()
    67. Aaron E Wagner, Amol J Ghia, Dennis C Shrieve, Kristine E Kokeny, William T Lowrance, Jonathan D Tward (12/01/2014). Adjuvant radiotherapy after prostatectomy: have randomized clinical trials had any impact? J Radiat Oncol, 3(4), 387-394.
    68. Bagshaw HP, Pappas LM, Kepka DL, Tward JD, Gaffney DK (2014). Patterns of care with brachytherapy for cervical cancer. Int J Gynecol Cancer, 24(9), 1659-64. ()
    69. Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, DAmico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M 3rd, Rohren E, Rosenfeld S, Schaeffer E, Small EJ, Sonpavde G, Srinivas S, Stein C, Strope SA, Tward J, Shead DA, Ho M, National Comprehensive Cancer Network (2014). Prostate cancer, version 2.2014. J Natl Compr Canc Netw, 12(5), 686-718. ()
    70. Burt LM, Shrieve DC, Tward JD (2014). Stage presentation, care patterns, and treatment outcomes for squamous cell carcinoma of the penis. Int J Radiat Oncol Biol Phys, 88(1), 94-100. ()
    71. ONeil BB, Presson A, Gannon J, Stephenson RA, Lowrance W, Dechet CB, Tward JD, Myers JB, Brant WO (2014). Climacturia after definitive treatment of prostate cancer. J Urol, 191(1), 159-63. ()
    72. Wagner AE, Chen A, Anker CJ, Tward JD, Ghia AJ, Jensen RL, Shrieve DC (2014). Stereotactic radiosurgery for a single brain metastasis: factors impacting control. J Radiosurg SBRT, 3(2), 111-121. ()
    73. Ghia AJ, Tward JD, Anker CJ, Boucher KM, Jensen RL, Shrieve DC (2014). Radiosurgery for melanoma brain metastases: the impact of hemorrhage on local control. J Radiosurg SBRT, 3(1), 43-50. ()
    74. Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, DAmico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kawachi MH, Kuettel M, Lee RJ, Macvicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Richey S, Roach M 3rd, Rohren E, Rosenfeld S, Small EJ, Srinivas S, Stein C, Strope SA, Tward J, Walsh PC, Shead DA, Ho M, National comprehensive cancer network (2013). Prostate cancer, version 1.2014. J Natl Compr Canc Netw, 11(12), 1471-9. ()
    75. Jason J Schwartz, Heather F Thiesset, William R Hutson, Lisa Hazard, Jonathan Tward, James Carlisle (11/25/2013). Complete Resolution of a Malignant Biliary Stricture Using Combined Neoadjuvant Chemoradiation and Brachytherapy Boost Prior to Orthotopic Liver Transplantation. J Liver Disease Transplant, 2(2).
    76. Jones G, Arthurs B, Kaya H, Macdonald K, Qin R, Fairbanks RK, Lamoreaux WT, Jawed I, Tward JD, Martincic D, Shivnani AT, Lee CM (2013). Overall survival analysis of adjuvant radiation versus observation in stage I testicular seminoma: a surveillance, epidemiology, and end results (SEER) analysis. Am J Clin Oncol, 36(5), 500-4. ()
    77. Tward JD, Kokeny KE, Shrieve DC (2013). Radiation therapy for clinically node-positive prostate adenocarcinoma is correlated with improved overall and prostate cancer-specific survival. Pract Radiat Oncol, 3(3), 234-240. ()
    78. Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, DAmico AV, Eastham JA, Enke CA, Farrington T, Higano CS, Horwitz EM, Kantoff PW, Kawachi MH, Kuettel M, Lee RJ, MacVicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Roach M 3rd, Rohren E, Rosenfeld S, Srinivas S, Strope SA, Tward J, Twardowski P, Walsh PC, Ho M, Shead DA (2012). Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw, 10(9), 1081-7. ()
    79. Cooke EW, Shrieve DC, Tward JD (2012). Clinical versus pathologic staging for prostate adenocarcinoma: how do they correlate? Am J Clin Oncol, 35(4), 364-8. ()
    80. Wang B, Tward JD, Salter BJ (2012). An evaluation of interference of inflatable penile prostheses with electromagnetic localization and tracking system. Med Phys, 39(8), 4807-11. ()
    81. Vern-Gross TZ, Shivnani AT, Chen K, Lee CM, Tward JD, MacDonald OK, Crane CH, Talamonti MS, Munoz LL, Small W Jr (2011). Survival outcomes in resected extrahepatic cholangiocarcinoma: effect of adjuvant radiotherapy in a surveillance, epidemiology, and end results analysis. Int J Radiat Oncol Biol Phys, 81(1), 189-98. ()
    82. ONeil B, Brant WO, Slack SD, Tward JD, Myers JB (2011). Penile Cancer: Contemporary Considerations in Management of Local Disease. Curr Urol, 5(2), 62-71.
    83. Rassiah-Szegedi P, Wang B, Szegedi M, Tward J, Zhao H, Huang YJ, Sarkar V, Shrieve D, Salter B (2011). Individualized margins for prostate patients using a wireless localization and tracking system. J Appl Clin Med Phys, 12(3), 3516. ()
    84. Barney BM, Hitchcock YJ, Sharma P, Shrieve DC, Tward JD (2011). Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer. Head Neck, 33(5), 645-9. ()
    85. Erickson BA, Demanes DJ, Ibbott GS, Hayes JK, Hsu IC, Morris DE, Rabinovitch RA, Tward JD, Rosenthal SA (2011). American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys, 79(3), 641-9. ()
    86. Ghia AJ, Gonzalez VJ, Tward JD, Stroup AM, Pappas L, Gaffney DK (2011). Primary vaginal cancer and chemoradiotherapy: a patterns-of-care analysis. Int J Gynecol Cancer, 21(2), 378-84. ()
    87. Ghia AJ, Shrieve DC, Tward JD (2010). Adjuvant radiotherapy use and patterns of care analysis for margin-positive prostate adenocarcinoma with extracapsular extension: postprostatectomy adjuvant radiotherapy: a SEER analysis. Urology, 76(5), 1169-74. ()
    88. Crosby MA, Tward JD, Szabo A, Lee CM, Gaffney DK (2010). Does brachytherapy improve survival in addition to external beam radiation therapy in patients with high risk stage I and II endometrial carcinoma? Am J Clin Oncol, 33(4), 364-9. ()
    89. Barney B, Tward JD, Skidmore T, Gaffney DK (2009). Does radiotherapy or lymphadenectomy improve survival in endometrial stromal sarcoma? Int J Gynecol Cancer, 19(7), 1232-8. ()
    90. Hitchcock YJ, Tward JD, Szabo A, Bentz BG, Shrieve DC (2009). Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients. Int J Radiat Oncol Biol Phys, 73(3), 779-88. ()
    91. Tward JD, Cachoeira CV, Salama ME, Lee RJ, Bowen G, Perkins SL, Glenn M, Confer M, Gaffney DK (2009). Survival and recurrence in nonmycosis fungoides primary cutaneous lymphoma. Cancer J, 15(1), 87-92. ()
    92. Chen J, Tward JD, Shrieve DC, Hitchcock YJ (2008). Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma: analysis of the surveillance, epidemiology, and end results 1983-2002. Am J Clin Oncol, 31(5), 460-4. ()
    93. Hazard LJ, Tward JD, Shrieve DC (2008). Adjuvant EBRT improves survival in patients with lymph-node-negative pancreatic cancer. Nat Clin Pract Oncol, 5(8), 438-9. ()
    94. Skidmore TB, Lee CM, Abbott TM, Wiggins RH 3rd, Anderson GE, Tward JD, Hitchcock Y (2008). Gorham disease of the mandible: radiographic findings and radiotherapy response. Ear Nose Throat J, 87(6), E4-7. ()
    95. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD (2008). The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab, 93(2), 504-15. ()
    96. Hazard L, Tward JD, Szabo A, Shrieve DC (2007). Radiation therapy is associated with improved survival in patients with pancreatic adenocarcinoma: results of a study from the Surveillance, Epidemiology, and End Results (SEER) registry data. Cancer, 110(10), 2191-201. ()
    97. Lee CM, Szabo A, Shrieve DC, Macdonald OK, Tward JD, Skidmore TB, Gaffney DK (2007). Descriptive nomograms of adjuvant radiotherapy use and patterns of care analysis for stage I and II endometrial adenocarcinoma: A surveillance, epidemiology, and end results population study. Cancer, 110(9), 2092-100. ()
    98. Tward JD, Shrieve, DC (2007). Brachytherapy Monotherapy for Older Men with Prostate Cancer. J Aging ÈËÆÞÖгöÊÓƵ, 3(5), 653-661.
    99. Hitchcock YJ, Bentz BG, Sharma PK, Fang C, Tward JD, Pappas L, Chen J, Hayes JK, Shrieve DC (2007). Planned neck dissection after definitive radiotherapy or chemoradiation for base of tongue cancers. Otolaryngol Head Neck Surg, 137(3), 422-7. ()
    100. Tward JD, Glenn M, Pulsipher M, Barnette P, Gaffney DK (2007). Incidence, risk factors, and pathogenesis of second malignancies in patients with Non-Hodgkin lymphoma. Leuk Lymphoma, 48(8), 1482-1495.
    101. Tward J, Glenn M, Pulsipher M, Barnette P, Gaffney D (2007). Incidence, risk factors, and pathogenesis of second malignancies in patients with non-Hodgkin lymphoma. Leuk Lymphoma, 48(8), 1482-95. ()
    102. Macdonald OK, Lee RJ, Snow G, Lee CM, Tward JD, Middleton AW, Middleton GW, Sause WT (2007). Prostate-specific antigen control with low-dose adjuvant radiotherapy for high-risk prostate cancer. Urology, 69(2), 295-9. ()
    103. Tward JD, Lee CM, Pappas LM, Szabo A, Gaffney DK, Shrieve DC (2006). Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment: impact of age at diagnosis. Cancer, 107(10), 2392-400. ()
    104. Macdonald OK, Lee CM, Tward JD, Chappel CD, Gaffney DK (2006). Malignant phyllodes tumor of the female breast: association of primary therapy with cause-specific survival from the Surveillance, Epidemiology, and End Results (SEER) program. Cancer, 107(9), 2127-33. ()
    105. Tward JD, Wendland MM, Shrieve DC, Szabo A, Gaffney DK (2006). The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer, 107(1), 108-15. ()
    106. Furie BC, Ratcliffe JV, Tward J, Jorgensen MJ, Blaszkowsky LS, DiMichele D, Furie B (1997). The gamma-carboxylation recognition site is sufficient to direct vitamin K-dependent carboxylation on an adjacent glutamate-rich region of thrombin in a propeptide-thrombin chimera. J Biol Chem, 272(45), 28258-62. ()
    107. Price MJ, Li LT, Tward JD, Bublik I, McBride WH, Lavey RS (1995). Effect of nicotinamide and pentoxifylline on normal tissue and FSA tumor oxygenation. Acta Oncol, 34(3), 391-5. ()
    108. Lavey RS, Taylor JM, Tward JD, Li LT, Nguyen AA, Chon Y, McBride WH (1994). The extent, time course, and fraction size dependence of mouse spinal cord recovery from radiation injury. Int J Radiat Oncol Biol Phys, 30(3), 609-17. ()

    Review

    1. Tward JD (06/28/2015). Editorial Review of: A Phase III Randomized Trial of MRI-Mapped, Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial. [Review]. 1(1).

    Edited Book

    1. Gaffney DK, Shrieve DC, Anker CJ, Buyyounouski MK, Kong F, Hitchcock YJ, Tward JD (Eds.) (2012). Radiation Oncology: Imaging and Treatment. (1st). Salt Lake City: Amirsys.

    Book Chapter

    1. Jonathan D Tward (1/1/2016). Prostate Cancer Bone Metastasis. In R. Lor Randall (Ed.), Metastatic Bone Disease - An integrated Approach to Patient Care (!st Edition). New York: Springer-Verlag.
    2. Hilary P Bagshaw, Jonathan D Tward (1/1/2016). Current and Emerging Modalities. In R. Lor Randall (Ed.), Metastatic Bone Disease -- An Integrated Approach to Patient Care (1st Edition). New York: Springer Verlag.
    3. Jonathan D Tward, Christopher J Anker, David K Gaffney and Glen M Bowen (March 2012). Radiation Therapy and Skin Cancer. In Modern Practices in Radiation Therapy.
    4. Ellen Cooke, Jonathan D Tward, Dennis C Shrieve (2011). Anus and Rectum. In Dennis C. Shrieve, Jay S. Loeffler (Eds.), Human Radiation Injury (1st). Lippincott Williams and Wilkins.

    Editorial

    1. Spratt DE, Tward JD (2020). Absolute versus Relative Benefit of Androgen Deprivation Therapy for Prostate Cancer: Moving Beyond the Hazard Ratio to Personalize Therapy. Int J Radiat Oncol Biol Phys, 108(4), 899-902. ()

    Letter

    1. Tward J, Lenz L (2022). In Regard to Dess. [Letter to the editor]. Int J Radiat Oncol Biol Phys, 115(1), 261-263. ()
    2. Shprecher DR, Grossmann KF, Tward JD (2014). Sustained remission of Parkinson disease associated melanoma with immunotherapy. [Letter to the editor]. Parkinsonism Relat Disord, 20(9), 1027-9. ()

    Abstract

    1. Praful Ravi, Gregory Russell Pond, Leonidas Nikolaos Diamantopoulos, Rohit K Jain, William Paul Skelton, Sumati Gupta, Jonathan David Tward, Kathleen Olson, Parminder Singh, Camilla Marisa Grunewald, Guenter Niegisch, Jae-Lyun Lee, Andrea Gallina, Marco Bandini, Andrea Necchi, Matthew Mossanen, Bradley Alexander McGregor, Catherine Curran, Petros Grivas, Guru Sonpavde (2020). Dissecting outcomes of patients (pts) with <ypT2N0 disease after neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC): Results from a large, international, multicenter collaboration. [Abstract]. 38(suppl), abstr 5043.
    2. Hunt T, Greenberg S, Ambrose J, ONeil B, Tward JD (2020). Factors associated with positive germline testing results in men with prostate cancer following NCCN guideline expansion. [Abstract]. 38(suppl 6), abstr 230.
    3. Jonathan David Tward, Thorsten Schlomm, Stephen Bardot, Stephen J Freedland, Lauren Lenz, Todd Cohen, Steven Stone, Jay Bishoff (2020). Ability of the combined clinical cell-cycle risk score to identify patients that benefit from multi versus single modality therapy in NCCN intermediate and high-risk prostate cancer. [Abstract]. 38(Suppl 6), abstr 346.
    4. Rebecca Levin-Epstein, Tahmineh Romero, Jessica Karen Wong, Kiri Cook, Robert Timothy Dess, Daniel Eidelberg Spratt, Brian Joseph Moran, Gregory Stephen Merrick, Phuoc T Tran, David Jeffrey Demanes, Brad J Stish, Daniel J Krauss, Trude Baastad Wedde, Wolfgang Lilleby, Richard Stock, Jonathan David Tward, Michael L Steinberg, Eric M Horwitz, Rahul D Tendulkar, Amar Upadhyaya Kishan (2020). Impact of initial treatment selection on clinical outcomes after biochemical failure in radiorecurrent high-risk prostate cancer. [Abstract]. 38(Suppl 6), abstr 208.
    5. Sumati Gupta, Benjamin Louis Maughan, Christopher B Dechet, William Thomas Lowrance, Brock O Neil, Kristine E Kokeny, Shane Lloyd, Jonathan David Tward, Kenneth M Boucher, Neeraj Agarwal (2020). NEXT: A phase II, open-label study of nivolumab adjuvant to chemoradiation in patients (pts) with localized muscle invasive bladder cancer. [Abstract]. 38(Suppl 6), Abstr tps605.
    6. JD Tward, R Petragallo, T Farr, DC Shrieve (2018). Comparative Effectiveness of Surgery versus Radiation Therapy for NCCN High and Very High Risk Prostate Cancer [Abstract]. 102(3), e147.
    7. Stone S, Cooperberg M, Flake, D, Davis JW, Moul JW, Tward, JD, Brawer MK (2017). Evaluation of microarrays for measuring cell cycle progression (CCP) gene expression.  Steven Stone, Matthew R. Cooperberg, Darl D Flake, John W. Davis, Judd W. Moul, Jonathan David Tward, Michael K. Brawer; Myriad Genetics, Inc., Salt Lake City, UT; ÈËÆÞÖгöÊÓƵ of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; The ÈËÆÞÖгöÊÓƵ of Texas MD Anderson Cancer Center, Houston, TX; Duke Cancer Institute, Duke ÈËÆÞÖгöÊÓƵ Medical Center, Durham, NC; ÈËÆÞÖгöÊÓƵ of Utah Huntsman Cancer Hospital, Salt Lake City, UT; Myriad Genetic Laboratories, Inc., Salt Lake City, UT.  J Clin Oncol 35, 2017 (suppl; abstr e16566) [Abstract]. 35(15_suppl), e16566-e16566.
    8. Shore ND, Crawford ED, Cooperberg MR, Tward JD, Kaldate RR, Stone S, Brawer MK (2016). Reduction in therapeutic burden from use of CCP test in treatment decisions among newly diagnosed prostate cancer patients independent of Charlson Comorbidity Index [Abstract]. 34(15_suppl), e16572-e16572.
    9. Frandsen J, Orton A, Shrieve DC, Tward J (05/01/2016). Risk of Death from Prostate Cancer with and without Definitive Local Therapy When Primary or Secondary Gleason Pattern 5 Is Present: A Seer Analysis [Abstract]. Brachytherapy, 15, s202-203.
    10. Mitchell Bassett, Darshan Patel, Benjamin Breyer, Jonathan D Tward, Cameron Thorpe, Thomas Gaither, James Hotaling, William Brant, Jeremy Myers (4/1/2016). URINARY DIVERSION FOR COMPLICATIONS OF PROSTATE CANCER RADIATION TREATMENT [Abstract]. The Journal of Urology, 193(4), 251.
    11. Kefu Du, Chong Zhang, Angela Presson, Jonathan Tward, William Brant, Christopher Dechet (04/01/2016). Kefu Du, Chong Zhang, Angela Presson, Jonathan Tward, William Brant, Christopher Dechet [Abstract]. The Journal of Urology, 195(4), e1043.
    12. Yu-Huei Jessica Huang, Jonathan D Tward, Prema Rassiah, Hui Zhao, Vikren Sarkar, L Huang, Martin Szegedi, Kristine E Kokeny, Bill J Salter (06/01/2015). Feasibility of MRI-Based Preplan On Low Dose Rate Prostate Brachytherapy [Abstract]. Medical Physics, 42(6), 331906/.
    13. M Szegedi, H Zhao, P Rassiah, V Sarkar, J Huang, L Huang, JD Tward, K Kokeny, BJ Salter (04/01/2015). Clinical comparison of 2D transabdominal and 3D transperineal ultrasound image guidance methods for prostate RT [Abstract]. 3rd ESTRO Forum Proceedings, s494.
    14. BJ Salter, M Szegedi, JD Tward, H Zhao, V Sarkar, P Rassiah-Szegedi, L Huang, J Huang (04/01/2015). 3D transperineal ultrasound image guidance methods for prostate SBRT radiotherapy treatment [Abstract]. 3rd ESTRO Forum Proceedings, s460.
    15. Mitchell Bassett, Darshan Patel, Benjamin Breyer, Jonathan D Tward, Cameron Thorpe, Thomas Gaither, James Hotaling, William Brant, Jeremy Myers (04/01/2015). URINARY DIVERSION FOR COMPLICATIONS OF PROSTATE CANCER RADIATION TREATMENT [Abstract]. The Journal of Urology, 193(4), e251.
    16. Jonathan D Tward, Lindsay M Burt, Dennis C Shrieve (03/01/2015). Definitive treatment of localized prostate cancer: Time and geographic trends. presented at the Genitourinary Cancers Symposium [Abstract]. Journal of Clinical Oncology, 33.
    17. E David Crawford, Neal Shore, Peter T Scardino, John W Davis, Jonathan D Tward, Lowndes Harrison, Brent Evans, Lisa Fitzgerald, Steven Stone, Michael K Brawer (03/01/2015). Performance of CCP assay in an updated series of biopsy samples obtained from commercial testing. presented at: Genitourinary Cancers Symposium [Abstract]. Journal of Clinical Oncology, 33.
    18. Cameron S Thorpe, Jeremy B Myers, Dennis C Shrieve, Jonathan D Tward (03/01/2015). Grade 3 or higher morbidity requiring urologic surgical management following curative-intent radiotherapy of localized prostate cancer: Patient characteristics. presented at: Genitourinary Cancers Symposium [Abstract]. Journal of clinical oncology, 33.
    19. Lindsay MBurt, Dennis C Shrieve, Jonathan D Tward (03/01/2015). Prostate patterns of care. [Abstract]. Journal of clinical oncology, 33.
    20. E Crawford, N, Shore, P Scardino, J Davis, JD Tward, K Moyes, L Fitzgerald, S STone, M Brawer (09/01/2014). CCP Score Stratifies Risk for Prostate Cancer Patients at Biopsy: Initial Commercial Results [Abstract]. International journal of radiation oncology, biology, physics, 90(1), s433.
    21. E Crawford, N Shore, P Scardino, J David, JD Tward, L Harrison, K Moyes, L Fitzgerald, S Stone, M Brawer (02/01/2014). CCP score and risk stratification for prostate cancer patients at biopsy: Presented at the Genitourinary Cancers Symposium [Abstract]. Journal of Clinical Oncology, 32.
    22. vj gonzalez, c hullett, l Burt, P Rassiah, v Sarkar, JD Tward, LJ Hazard, JY Huang, BJ Salter, DK Gaffney (10/01/2013). Impact of Prone Versus Supine Positioning on Small Bowel Dose With Pelvic IMRT [Abstract]. International journal of radiation oncology, biology, physics, 87(2), s680.
    23. S Francis, CJ Anker, DG Adler, JD Tward, C Kristen, DC Shrieve (10/01/2013). The Effect of Stents on Acute Toxicity in Esophageal Cancer [Abstract]. International Journal of Radiation OncologyBiologyPhysics, 87(2), s296.
    24. H Bagshaw, JD Tward, D Gaffney (10/01/2013). Patterns of Care With Brachytherapy for Cervical Cancer [Abstract]. International Journal of Radiation OncologyBiologyPhysics, 87(2), s410.
    25. AE Wagner, AJ Ghia, K Kokeny, DC Shrieve, JD Tward (10/01/2013). Adjuvant Radiation Therapy After Prostatectomy: Have Randomized Clinical Trials Had Any Impact? [Abstract]. International Journal of Radiation OncologyBiologyPhysics, 87(2), s174.
    26. LM Burt, A Wagner, DC Shrieve, JD Tward (10/01/2013). Comparison of Treatments for Breast Cancer Arising After Radiation Treatment for Hodgkin Lymphoma [Abstract]. International Journal of Radiation OncologyBiologyPhysics, 87(2), s247.
    27. D Ly, CJ Anker, JD Tward, DC Shrieve (10/01/2013). Local Control After Stereotactic Radiosurgery (SRS) for Brain Metastases (BM) in Melanoma Patients With and Without BRAF Mutation and Treatment [Abstract]. International Journal of Radiation OncologyBiologyPhysics, 87(2), s282.
    28. B ONeil, A Presson, J Gannon, RA Stephenson, W Lowrance, C Dechet, JD Tward, J Myers, WO Brant (09/01/2013). Climacturia after Definitive Treatment of Prostate Cancer [Abstract]. The Journal of urology, 19(1).
    29. BJ Salter, Martin Szegedi, B Wang, JD Tward (06/01/2013). Presentation of a New Intrafractional Prostate Monitoring Method with Ultrasound Image Guidance During Radiotherapy Treatment [Abstract]. Medical Physics, 40(6), 375.
    30. B Wanfg, V Sarkar, P Rassiah, H Zhao, YH Huang, M Szegedi, DC Shrieve, JD Tward, BJ Salter (06/01/2013). Direct Clinical Comparison of 2D Versus 3D Transabdominal Ultrasound Image Guidance Methods for Prostate Radiotherapy Treatment [Abstract]. Medical Physics, 40(6), 375.
    31. JD Tward, WT Lowrance, DC Shrieve (2012). Demographics and Comparative Effectiveness of Surgery and Radiation Therapy in Men With Gleason Pattern 5 Prostate Cancer [Abstract]. International Journal of Radiation Oncology * Biology * Physics, 84(3), s386.
    32. C Hullett, VJ Gonzalez, L Burt, P Rassiah-Szegedi, V Sarkar, J Tward, LJ Hazard, J Huang, BJ Salter, DK Gaffney (2012). Impact of BMI on Daily Setup Variation With Pelvic Radiation Therapy: Is Prone Positioning a Class Solution? [Abstract]. International Journal of Radiation Oncology * Biology * Physics, 84(3), s726.
    33. D Ly, DC Shrieve, JD Tward (2012). Demographics, Prognostic Factors, and Treatment Outcomes of Adrenocorticotrophic Carcinoma: A SEER Database Analysis From 1988-2008 [Abstract]. International Journal of Radiation Oncology * Biology * Physics, 84(3), s424.
    34. BE Terakedis, ME Heilbrun, WT Lowrance, DC Shrieve, JD Tward (2012). The Effect of Prostate MRI on Cancer Staging and Radiation Therapy Treatment Recommendations [Abstract]. International Journal of Radiation Oncology * Biology * Physics Vol, 84(3), S363-S364.
    35. JD Tward, DC Shrieve (2011). Patterns of Care for Localized Prostate Cancer Stratified by Risk Group and Age at Diagnosis in the United States [Abstract]. International Journal of Radiation Oncology * Biology * Physics, 81(2), s102.
    36. MM Poppe, JD Tward, DC Shrieve (2011). Trend of Declining Radiotherapy Use in Pediatric Low Grade Glioma [Abstract]. International Journal of Radiation Oncology * Biology * Physics, 81(2), s657.
    37. JD Tward, DC Shrieve (2010). Radiotherapy is Correlated with Superior Survival in Clinically Node Positive Prostate Cancer [Abstract]. International Journal of Radiation Oncology * Biology * Physics, 78(3), s31.
    38. L Burt, DC Shrieve, JD Tward (2010). Stage Presentation, Care Patterns, and Treatment Outcomes for Squamous Cell Carcinoma of the Penis [Abstract]. International Journal of Radiation Oncology * Biology * Physics, 78(3), s32-s33.
    39. M Szegedi, P Rassiah-Szegedi, Y Huang, JD Tward, H Zhao, D Shrieve, and B Salter (2010). Post Implant Dosimetry for I 125 and Pd 103 Anchor and Non Anchor Seeds [Abstract]. Medical Physics, 37(6), 3201.
    40. ME Montejo, B Bentz, J Hunt, J Tward, DC Shrieve, YJ Hitchcock (2009). IMRT with Simultaneous Integrated Boost (IMRT-SIB) Radiotherapy and Concurrent Cisplatin for Locoregional Advanced Squamous Cell Carcinoma of Head and Neck [Abstract]. International Journal of Radiation Oncology * Biology * Physics, 75(3), s416-s417.
    41. P Rassiah, B Wang, M Szegedi, H Zhao, Y Huang, JD Tward, DC Shrieve, BJ Salter (2009). Characterization of Potential Radiobiological Benefit from Design of Patient-specific Margins for Prostate Conformal Treatment using a Real Time Tracking System [Abstract]. International Journal of Radiation Oncology * Biology * Physics, 75(3), S586-S587.
    42. AJ Ghia, DC Shrieve, JD Tward (2009). Adjuvant Radiotherapy Use and Patterns of Care Analysis for Margin Positive Prostate Adenocarcinoma with Extracapsular Extension [Abstract]. International Journal of Radiation Oncology * Biology * Physics, 75(3), S309.
    43. EW Cooke, DC Shrieve, JD Tward (2009). Pathologic Staging Results in Substantially Higher Risk-stratification Compared with that Predicted by Clinical Risk-stratification in Men with Adenocarcinoma of the Prostate [Abstract]. International Journal of Radiation Oncology * Biology * Physics, 75(3), S297-S298.
    44. EW Cooke, DC Shrieve, JD Tward (2009). Pathologic Staging Results in Substantially Higher Risk-stratification Compared with that Predicted by Clinical Risk-stratification in Men with Adenocarcinoma of the Prostate [Abstract]. International Journal of Radiation Oncology * Biology * Physics, 75(3), S297-S298.
    45. BJ Salter, B Wang, JD Tward, DC Shrieve (2009). Investigation of Potential Interference of 3 Piece Penile Prostheses with Electromagnetic Localization System [Abstract]. International Journal of Radiation Oncology * Biology * Physics, 75(3), S605-S606.
    46. Y Huang, B Wang, J Tward, D Shrieve, and B Salter (2009). A Comparison of Calypso Based Localization for Post Prostatectomy Patient in the Presence of High Geometric Residual (GR) Beacon Error: Comparison/correlation with Ultrasound Alignment [Abstract]. Medical Phsyics, 36(6), 2480.
    47. P Rassiah-Szegedi, B Wang, JD Tward, M Szegedi, H Zhao, and B Salter (2009). Dosimetric Feasibility of Patient-Specific Margins for Prostate Patients Using a Wireless Localization and Tracking System [Abstract]. Medical Physics, 36(6), 2497.
    48. Tward JD, JE Sylvester, PD Grimm, DC Shrieve (2008). The Risk of Second Primary Malignancies Following Brachytherapy Monotherapy, External Beam Plus Brachytherapy, or Radical Prostatectomy for Prostate Cancer [Abstract]. International Journal of Radiation Oncology, Biology, Physics, 72(1 supp 1), S94.
    49. K De Amorim Bernstein, Tward JD, DC Shrieve (2008). Patterns of Care for Prostate Cancer in the USA: Results from the SEER Database [Abstract]. International Journal of Radiation Oncology, Biology, Physics, 72(1 Supp 1), S134.
    50. BJ Salter, B Wang, M Szegedi, Tward JD, DC Shrieve (2008). Prostate Displacement during and after Transabdominal Ultrasound (US) Guidance, Monitored by a Real-time Tracking System [Abstract]. International Journal of Radiation Oncology, Biology, Physics, 72(1 Supp 1), S146-S147.
    51. Tward JD, Cachoeira CV, Salama ME, Lee RJ, Bowen G, Perkins SL, Glenn M, Confer M, Gaffney DK (2008). Survival and Recurrence in Non-Mycosis Fungoides Primary Cutaneous Lymphoma [Abstract]. Proceedings of American Radium Society 90th Annual Meeting, 1(1).
    52. Salama M, Ho A, Tward JD, Gaffney DK, Perkins SL (2008). BCL2 expression in primary cutaneous follicle center lymphoma: clinicopathologic study of 15 cases. [Abstract]. Proceedings of the United States and Canadian Academy of Pathology Annual Meeting, March 1 - March 7, 2008, 1(1).
    53. Tward JD, Stephenson R, Dechet C, Shrieve DC (2008). Overall and cause-specific survival comparison in men undergoing prostatectomy versus external beam radiotherapy for prostate cancer with seminal vesicle invasion. [Abstract]. 2008 Genitourinary Cancers Symposium Proceedings, 1(1).
    54. AT Shivnani, CM Lee, Tward JD, O Macdonald, LL Munoz, C Crane, MS Talamonti, W Small (2007). Survival Outcomes for Adjuvant Radiation Therapy Versus no Radiation Therapy in Extrahepatic Cholangiocarcinoma: A Surveillance, Epidemiology, and End Results (SEER) Analysis [Abstract]. International Journal of Radiation Oncology, Biology, Physics, 69(3, Supp 1), S283.
    55. N Vudarla, I Jawed, H Kaya, Tward JD, O K Macdonald, D Martincic, D K Gaffney, A T Shivnani, T L Odom- Maryon, and C M Lee (2007). Survival and secondary malignancy rates for adjuvant radiation therapy versus observation in stage I testicular seminoma: A Surveillance, Epidemiology, and End Results (SEER) analysis [Abstract]. Journal of Clinical Oncology, 25(18S).
    56. I Jawed, C M Lee, Tward JD, O K Macdonald, D Martincic, N Vudarla, R K Fairbanks, and H Kaya (2007). Survival outcomes for multiple myeloma over three decades: A Surveillance, Epidemiology, and End Results (SEER) analysis [Abstract]. Journal of Clinical Oncology, 25(18s).
    57. Tward JD, Hitchcock YJ, Sharma P, Shrieve DC (2007). Overall and Cause-Specific Survival for Patients Undergoing Lobectomy, Near-Total, or Total Thyroidectomy for Differentiated Thyroid Cancer: Is there a Difference? [Abstract]. Proceedings of the Multidisciplinary Head and Neck Cancer Symposium 2007, 1(1).
    58. CM Lee, A Szabo, DC Shrieve, OK Macdonald, Tward JD, DK Gaffney (2006). External Beam Radiation With or Without Vaginal Brachytherapy in Stage IC-II Endometrial Adenocarcinoma Provides a Survival Advantage: A Surveillance, Epidemiology, and End Results (SEER) Population Analysis [Abstract]. International Journal of Radiation Oncology, Biology, Physics, 66(3 Supp 1), S39-S40.
    59. LJ Hazard, Tward JD, J O8217Connor, D Shrieve (2006). Pre and Post-Operative Radiation Therapy is Associated With Improved Survival in Patients With Pancreatic Adenocarcinoma: Results of a Study From the Surveillance, Epidemiology, and End Results (SEER) Registry Data [Abstract]. International Journal of Radiation Oncology, Biology, Physics, 66(3, Supp 1), S81-83.
    60. Tward JD, A Szabo, R Orlandi, L Dahlstrom, DC Shrieve, YJ Hitchcock (2006). Relative Contributions of Radiation and Platinum-Based Chemotherapy to Sensorineural Hearing Loss in Head and Neck Cancer PatientsInternational Journal of Radiation Oncology*Biology*Physics, Volume 66, Issue 3, Supplement 1, 1 November 2006, Page S188 [Abstract]. International Journal of Radiation Oncology, Biology, Physics, 66(3, Supp 1), s188.
    61. OK Macdonald, CM Lee, Tward JD, CD Chappell, DK Gaffney (2006). Malignant Phyllodes Tumor of the Female Breast: Determinants of Cause-Specific Survival From the Surveillance, Epidemiology, and End Results: (SEER) Program [Abstract]. International Journal of Radiation Oncology, Biology, Physics, 66(3, Supp 1), S212.
    62. YJ Hitchcock, K Morton, Tward JD, JM Hoffman, P Sharma, B Bentz, DC Shrieve (2006). The Application of [18FDG] PET/CT in Treatment Planning and Response Evaluation for Patients Undergoing Radiotherapy for Head and Neck Cancer [Abstract]. International Journal of Radiation Oncology, Biology, Physics, 66(3, Supp 1), S433-S434.
    63. AP Brown, Tward JD, J Chen, DC Shrieve, YJ Hitchcock (2006). The Risk of Development and Factors Affecting the Pattern of Secondary Cancers Following Thyroid Cancer Diagnosis [Abstract]. International Journal of Radiation Oncology, Biology, Physics, 66(3, Supp 1), S434.
    64. Tward JD, Shrieve, DC (2006). The Risk of Development and Factors Affecting the Pattern of Secondary Cancers Following Diagnosis of Wilm’s Tumor [Abstract]. Proceedings of the American Radium Society 88th Annual Meeting, 1(1).
    65. Lee, CM, MacDonald, K, Tward JD, Shrieve, DC, Szabo, A, Gaffney, DK (2006). Patterns of care analysis of adjuvant therapy in the United States for stage I-II endometrial adenocarcinoma: A surveillance, epidemiology, and end results (SEER) population analysis. [Abstract]. Gynecologic Oncology, 101(1, Supp 1).
    66. Tward JD, Szabo, A, Gaffney, DK, Shrieve, DC (2005). Does Age at Diagnosis Affect Outcome for Men Treated by Brachytherapy Versus Surgery for Clinically Localized Prostate Cancer? [Abstract]. Brachytherapy, 4(2), 79-120.
    67. Tward JD, Shrieve, DC, Szabo, A, Gaffney, DK (2005). Does Radiotherapy Alter the Pattern of Secondary Malignancies after the Treatment of Non-Hodkin’s Lymphoma [Abstract]. Proceedings of the 87th annual meeting of the American Radium Society, Barcelona, Spain, 1(1), 1.
    68. Tward JD, Furie, BC, Jacobs, M, Furie, B (2000). A nine amino acid motif is sufficient to direct gamma carboxylation in-vitro [Abstract]. Blood, 96(11).
    69. Tward JD, Furie, BC, Bouchard, BA, Jacobs, M, Furie, B (1998). The vitamin K-dependent gamma glutamyl carboxylase recognition sequence: refinement of the model. [Abstract]. Blood (Ash Annual Meeting Abstracts) 1998, 92(Supp).
    70. Tward JD, Furie, BC, Bouchard, BA, Jacobs, M, Furie, B (1997). Other amino acids than phenylalanine at position –16 in the carboxylation recognition site in the prothrombin propeptide can support gamma-carboxylation. [Abstract]. Blood (ASH Annual Meeting Abstracts) 1997, 90(Supp).
    71. Lavey, RS, Li, LT, Bublick, I, Tward JD, McBride, WH (1995). Elevation of hematocrit by recombinant human erythropoietin (r-HuEPO) improves tumor oxygenation. [Abstract]. Proceedings of the 77th Annual Meeting of the American Radium Society, Paris, France, 1(1).
    72. Lavey, RS, Tward JD, Li, LT, Brooks, J, McBride, WH, Dempsey, WH, Dewhirst, MW, Brizel, DM (1994). Hematocrit is significantly associated with the oxygenation of murine Fsa tumors [Abstract]. International Journal of Radiation Oncology, Biology, Physics, 31(Supplement).
    73. Lavey, RS, Tward JD, Li, LT, McBride, WH (1994). Interactive effects of interleukin-2 and radiation on pulmonary metastases and normal tissue function. [Abstract]. Proceedings of the 13th Annual Meeting of the European Society for therapeutic Radiology and Oncology, Granada, Spain.
    74. Price, M, Tward JD, Li, LT, McBride, WH, Lavey, RS (1994). Effect of nicotinamide and pentoxyfylline on normal tissue and Fsa tumor oxygenation. [Abstract]. Proceedings of the International Workshop on the Tumor Microenvironment: Its Characterization, Modification and Clinical Implications, Granada, Spain.

    Other

    1. Xiang M, Ma TM, Savjani R, Pollom EL, Karnes RJ, Grogan T, Wong JK, Motterle G, Tosoian JJ, Trock BJ, Klein EA, Stish BJ, Dess RT, Spratt DE, Pilar A, Reddy C, Levin-Epstein R, Wedde TB, Lilleby WA, Fiano R, Merrick GS, Stock RG, Demanes DJ, Moran BJ, Huland H, Tran PT, Martin S, Martinez-Monge R, Krauss DJ, Abu-Isa EI, Alam R, Schwen Z, Pisansky TM, Choo CR, Song DY, Greco S, Deville C, McNutt T, DeWeese TL, Ross AE, Ciezki JP, Boutros PC, Nickols NG, Bhat P, Shabsovich D, Juarez JE, Chong N, Kupelian PA, Rettig MB, Zaorsky NG, Berlin A, Tward JD, Davis BJ, Reiter RE, Steinberg ML, Elashoff D, Horwitz EM, Tendulkar RD, Tilki D, Czernin J, Gafita A, Romero T, Calais J, Kishan AU (2021). Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. JAMA Netw Open (4(12), pp. e2138550). United States. ()
    2. Himbert C, Hathaway CA, Daniels B, Salas K, Ashworth A, Gigic B, Lin T, Viskochil R, Kirchhoff AC, Grossman D, Ose J, Tward J, Scaife C, Figueiredo JC, Toriola AT, Beck A, Shibata D, Gonzalez BD, Matsen C, Christenson C, Ma DS, Colman H, Hunt JP, Jones KB, Lee CJ, Larson M, Onega T, Akerley WL, Li CI, Schneider M, Penedo FJ, Siegel EM, Tworoger SS, Ulrich CM, Peoples AR (2021). Impact of the COVID-19 pandemic on exercise habits among cancer patients. Res Sq. United States. ()

    Video/Film/CD/Web/Podcast

    1. Jonathan Tward (01/23/2015). Abbreviated Course ADT for Prostate Cancer [Web]. San Francisco: OncLive. Available: http://www.onclive.com/onclive-tv/Dr-Tward-on-Abbreviated-Course-ADT-for-Prostate-Cancer-.
    2. Jonathan Tward (07/23/2014). Is Death From Prostate Cancer the Right Clinical Endpoint to Guide Screening and Treatment Choices? [Web]. Salt Lake City: OncLive. Available: http://www.onclive.com/publications/Oncology-live/2014/June-2014/Is-Death-From-Prostate-Cancer-the-Right-Clinical-Endpoint-to-Guide-Screening-and-Treatment-Choices.

    Patent

    1. Jonathan Tward, Paisley Tarboton, Zachary B. Barber, Jessica Reimer (2019). URINARY CONTROL DEVICE. U.S. Patent No. pending. Washington, D.C.:U.S. Patent and Trademark Office.

  • News & Podcasts

    Huntsman Cancer Institute News

    Podcasts